Applications

Applications

Applications

Home Applications Endovascular Peripheral GORE® VIATORR® TIPS Endoprosthesis

Peripheral

GORE® VIATORR® TIPS Endoprosthesis
 
 

Purpose-built for TIPS

The only covered stent for TIPS with controlled expansion and 25 years of performance and safety data.a

Built for lasting performance

The VIATORR® Device allows you to tailor the diameter and target a portal pressure gradient for each patient’s needs.

Select a device feature to learn more.

A flat diagram showing GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion

ALTA-recommended for TIPS placement

The American Liver Therapeutic Approaches (ALTA) group recommends "the use of an ePTFE-lined stent graft with controlled expansion, which allows the operator to tailor the amount of portosystemic shunting based on the indication, target gradient and patient comorbidities.”1

Built for long-term results

76%

Two-year primary patency2

The VIATORR® Device was proven to maintain TIPS patency over time in a randomized controlled study (N = 80)2

Built for improved outcomes

Patients treated with the VIATORR® Device have a higher one-year survival than those treated with non-TIPS therapy.1,3,4

Variceal bleeding outcomes

Early TIPS compared to drug therapy plus endoscopic band ligation (EBL) for variceal bleeding4

86%

1-year survival

following early TIPS procedure with the VIATORR® Device, compared to 61% 1-year survival following pharmacotherapy plus endoscopic band ligation (P < 0.001)c,4

97%

1-year control of bleeding

following early TIPS procedure with the VIATORR® Device, compared to 50% 1-year survival following pharmacotherapy plus endoscopic band ligation (P < 0.001)d,4

0

No increase in the risk of hepatic encephalopathy

at 1 year, compared to pharmacotherapy plus endoscopic band ligation (P = 0.13)4

Refractory ascites outcomes

Early TIPS compared to large volume paracenteses (LVP) and albumin for refractory ascites3

Checkmark icon

Improved survival

TIPS with the VIATORR® Device demonstrated higher transplant-free survival (93%), compared to large volume paracenteses (LVP) and albumin infusion (52%) (P = .003)3

Less ascites icon

Fewer paracenteses

with 1 paracentesis procedure required to treat ascites following placement of the VIATORR® Device, compared to 10 procedures with paracentesis treatment alone3

Not allowed icon

No increase in the risk of hepatic encephalopathy

at 1 year, compared to LVP and albumin infusion (P = .868)3

   GORE VIATORR TIPS Endoprosthesis with Controlled Expansion video thumbnail.